Microablative Fractional CO2 Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer: A Pilot Study at 4-week Follow-up

Stefano Salvatore; Rossella E. Nappi; Arianna Casiraghi; Alessandro F. Ruffolo; Rebecca Degliuomini; Marta Parma; Umberto Roberti Leone Maggiori; Stavros Athanasiou; Massimo Candiani

doi:10.1016/j.clbc.2021.01.006

Microablative Fractional CO₂ Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer: A Pilot Study at 4-week Follow-up

Stefano Salvatore, Rossella E. Nappi, Arianna Casiraghi, Alessandro F. Ruffolo, Rebecca Degliuomini, Marta Parma, Umberto Roberti Leone Maggiori, Stavros Athanasiou, Massimo Candiani

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of this pilot study is to assess the efficacy and safety of microablative fractional CO₂ laser for treating vulvovaginal (VVA) symptoms in women with a history of breast cancer (BC) at 20-week follow-up since the first laser treatment. We enrolled 40 women with a history of BC and who currently were or had been on treatment with endocrine therapy for their condition. Each of them was treated with 5 laser applications (one every 4 weeks), and the effects of the laser treatment on VVA symptoms were measured using a 10-cm visual analog scale after 20 weeks of follow-up. Changes in the Vaginal Health Index after treatment were compared with baseline. Changes in overall quality of life were assessed with a generic quality of life questionnaire: Short Form 12. Sexual function was evaluated by the Female Sexual Function Index. After 20 weeks of follow-up, microablative fractional CO₂ laser was safe and effective in treating VVA symptoms in women with a history of BC, irrespective of being previously or currently on endocrine therapies.

Original language	English
Journal	Clinical Breast Cancer
DOIs	https://doi.org/10.1016/j.clbc.2021.01.006
Publication status	Accepted/In press - 2021

Keywords

Dyspareunia
Menopause
Sexual function
Sexual intercourse
Vaginal dryness

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.clbc.2021.01.006

Cite this

Salvatore, S., Nappi, R. E., Casiraghi, A., Ruffolo, A. F., Degliuomini, R., Parma, M., Roberti Leone Maggiori, U., Athanasiou, S., & Candiani, M. (Accepted/In press). Microablative Fractional CO₂ Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer: A Pilot Study at 4-week Follow-up. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2021.01.006

Microablative Fractional CO₂ Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer : A Pilot Study at 4-week Follow-up. / Salvatore, Stefano ; Nappi, Rossella E.; Casiraghi, Arianna; Ruffolo, Alessandro F.; Degliuomini, Rebecca; Parma, Marta; Roberti Leone Maggiori, Umberto; Athanasiou, Stavros; Candiani, Massimo.

In: Clinical Breast Cancer, 2021.

Research output: Contribution to journal › Article › peer-review

Salvatore, Stefano ; Nappi, Rossella E. ; Casiraghi, Arianna ; Ruffolo, Alessandro F. ; Degliuomini, Rebecca ; Parma, Marta ; Roberti Leone Maggiori, Umberto ; Athanasiou, Stavros ; Candiani, Massimo. / Microablative Fractional CO₂ Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer : A Pilot Study at 4-week Follow-up. In: Clinical Breast Cancer. 2021.

@article{19c582114cfd41bba216199b017925ee,

title = "Microablative Fractional CO2 Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer: A Pilot Study at 4-week Follow-up",

abstract = "The aim of this pilot study is to assess the efficacy and safety of microablative fractional CO2 laser for treating vulvovaginal (VVA) symptoms in women with a history of breast cancer (BC) at 20-week follow-up since the first laser treatment. We enrolled 40 women with a history of BC and who currently were or had been on treatment with endocrine therapy for their condition. Each of them was treated with 5 laser applications (one every 4 weeks), and the effects of the laser treatment on VVA symptoms were measured using a 10-cm visual analog scale after 20 weeks of follow-up. Changes in the Vaginal Health Index after treatment were compared with baseline. Changes in overall quality of life were assessed with a generic quality of life questionnaire: Short Form 12. Sexual function was evaluated by the Female Sexual Function Index. After 20 weeks of follow-up, microablative fractional CO2 laser was safe and effective in treating VVA symptoms in women with a history of BC, irrespective of being previously or currently on endocrine therapies.",

keywords = "Dyspareunia, Menopause, Sexual function, Sexual intercourse, Vaginal dryness",

author = "Stefano Salvatore and Nappi, {Rossella E.} and Arianna Casiraghi and Ruffolo, {Alessandro F.} and Rebecca Degliuomini and Marta Parma and {Roberti Leone Maggiori}, Umberto and Stavros Athanasiou and Massimo Candiani",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

doi = "10.1016/j.clbc.2021.01.006",

language = "English",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier",

}

TY - JOUR

T1 - Microablative Fractional CO2 Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer

T2 - A Pilot Study at 4-week Follow-up

AU - Salvatore, Stefano

AU - Nappi, Rossella E.

AU - Casiraghi, Arianna

AU - Ruffolo, Alessandro F.

AU - Degliuomini, Rebecca

AU - Parma, Marta

AU - Roberti Leone Maggiori, Umberto

AU - Athanasiou, Stavros

AU - Candiani, Massimo

PY - 2021

Y1 - 2021

N2 - The aim of this pilot study is to assess the efficacy and safety of microablative fractional CO2 laser for treating vulvovaginal (VVA) symptoms in women with a history of breast cancer (BC) at 20-week follow-up since the first laser treatment. We enrolled 40 women with a history of BC and who currently were or had been on treatment with endocrine therapy for their condition. Each of them was treated with 5 laser applications (one every 4 weeks), and the effects of the laser treatment on VVA symptoms were measured using a 10-cm visual analog scale after 20 weeks of follow-up. Changes in the Vaginal Health Index after treatment were compared with baseline. Changes in overall quality of life were assessed with a generic quality of life questionnaire: Short Form 12. Sexual function was evaluated by the Female Sexual Function Index. After 20 weeks of follow-up, microablative fractional CO2 laser was safe and effective in treating VVA symptoms in women with a history of BC, irrespective of being previously or currently on endocrine therapies.

AB - The aim of this pilot study is to assess the efficacy and safety of microablative fractional CO2 laser for treating vulvovaginal (VVA) symptoms in women with a history of breast cancer (BC) at 20-week follow-up since the first laser treatment. We enrolled 40 women with a history of BC and who currently were or had been on treatment with endocrine therapy for their condition. Each of them was treated with 5 laser applications (one every 4 weeks), and the effects of the laser treatment on VVA symptoms were measured using a 10-cm visual analog scale after 20 weeks of follow-up. Changes in the Vaginal Health Index after treatment were compared with baseline. Changes in overall quality of life were assessed with a generic quality of life questionnaire: Short Form 12. Sexual function was evaluated by the Female Sexual Function Index. After 20 weeks of follow-up, microablative fractional CO2 laser was safe and effective in treating VVA symptoms in women with a history of BC, irrespective of being previously or currently on endocrine therapies.

KW - Dyspareunia

KW - Menopause

KW - Sexual function

KW - Sexual intercourse

KW - Vaginal dryness

UR - http://www.scopus.com/inward/record.url?scp=85102847821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102847821&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2021.01.006

DO - 10.1016/j.clbc.2021.01.006

M3 - Article

AN - SCOPUS:85102847821

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -